Navigation Links
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting

ts.

Discovery's lead product candidate, Surfaxin(r), is the subject of an Approvable Letter from the FDA for the prevention of Respiratory Distress Syndrome in premature infants. Surfaxin is also being developed for other neonatal and pediatric indications. Aerosurf(tm), Discovery's aerosolized SRT, is being developed to potentially obviate the need for intubation and conventional mechanical ventilation and holds the promise to significantly expand the use of surfactants in respiratory medicine. For more information, please visit our website at www.Discoverylabs.com.

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Among the factors which could affect Discovery's actual results and could cause results to differ from those contained in these forward-looking statements are the risk that Discovery may not profitably develop and market its products, the risk that financial market conditions may change, the risk that Discovery will not be able to raise additional capital or enter into additional collaboration agreements, the risk that Discovery will not be able to attract or retain qualified personnel or timely provide for a successful sales and marketing organization, risks relating to the progress of Discovery's research and development,, risks in the FDA or other regulatory agency review process generally, including that such regulatory authority will not approve the marketing and sale of a drug product even after acceptance of an application or that approval by such regulatory agency may be withheld, delayed and/or limited by indications or other label limita
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:8/20/2014)... Trovagene, Inc. (NASDAQ:   TROV), a developer ... two clinical studies will be presented at the 29th ... test for the detection of high risk strains of ... take place in Seattle from ... a new U.S. patent was issued earlier this year ...
(Date:8/20/2014)... , August 20, 2014 ... Conducted in the US  KalVista Pharmaceuticals ("KalVista"), ... edema (DME), today announces that it has begun a ... plasma kallikrein inhibitor, KVD001, for the treatment of DME. ... of the Beetham Eye Institute, Joslin Diabetes Center; Harvard ...
(Date:8/19/2014)... , Aug. 19, 2014 Minimally Invasive Devices ... medical device company, announced today that Mitsubishi Corporation has ... robotic visualization system in Japan . ... in Japan in the second ... the exclusive distributor for Karl Storz GMBH & Co. ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2
(Date:8/20/2014)... 20, 2014 A common approach to treating kidney ... not improve survival chances for people who suddenly developed ... the University of Pittsburgh School of Medicine. , Their ... , suggest acute hemodialysis, an aggressive method that is ... not provide a definitive benefit to the patient. , ...
(Date:8/20/2014)... (August 20, 2014) Research from Columbia University Medical ... in stomach cancer growth and that blocking nerve signals ... treatment for the disease. The study was conducted by ... with Duan Chen, MD, PhD, in Norway and is ... . , "Scientists have long observed that human and ...
(Date:8/20/2014)... 20, 2014 The non-small cell lung ... in the offing across the top 8 developed nations, ... to around USD 8 billion by 2020-end, posting a ... is projected to be driven by innovative therapies entering ... lacking efficient treatment, unlike the non-squamous segment. Thus, patients ...
(Date:8/20/2014)... Rosa, CA (PRWEB) August 20, 2014 The ... the 12 per diode panel band perfect spectrum that encompasses ... are most likely to use during photosynthesis. A key ... bands is that they almost exclusively reside between 440-480 on ... on the red side of the spectrum. The KIND LED ...
(Date:8/20/2014)... MI (PRWEB) August 20, 2014 In its ... drug and alcohol treatment program that gets clients off to ... recovery they can believe in, is highlighting an important and ... be heeded by everyone who wants to understand the insidious ... are of the belief that drug abuse targets a certain ...
Breaking Medicine News(10 mins):Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 3Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 4Health News:Cheap LED Grow Lights Are Quickly Being Replaced by Premium Grow Lights 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 3
... Oct. 20 Strong new pledges of,commitment ... donors, government,officials, corporations, foundations and non-governmental organizations,today ... Deliver conference, which,sought to mobilize political will ... worldwide. More than 1,800 participants from ...
... YORK, Oct. 20 EmPower Research, LLC, a ... Consulting, launched its,first-ever study on the Indian Contract ... titled ,Indian Contract Research Industry, (CRO-nicles),captures the industry,s ... to the top line industry executives first hand. ...
... Following is a statement,by Linda A. Suydam, D.P.A., ... the recommendations issued today by the U.S.,Food and ... Committee. At a meeting this week, the joint ... medicines in children., "For decades, parents and ...
... Court, WILMINGTON, Del., Oct. 19 The following,statement ... W.Va., zinc,smelter class action lawsuit. The statement is to ... "We are extremely disappointed by the outcome of the ... unfairly punished for doing,the right thing for this property ...
... Mass., Oct. 19 LeMaitre Vascular,Inc. (Nasdaq: ... and implants for the treatment of peripheral vascular ... Annual Healthcare Conference on,Tuesday, November 6, 2007, in ... George W. LeMaitre, Chairman and Chief Executive Officer, ...
... the less the idea bothered her , , FRIDAY, Oct. ... the idea of childlessness than men, new research shows, ... how each gender views the pressures of parenthood. , ... and parenthood mean different things," said study author Tanya ...
Cached Medicine News:Health News:Women Deliver Conference Launches New Commitments 2Health News:EmPower Research Launches Indian CRO Industry Report 2Health News:Statement from the Consumer Healthcare Products Association on Today's Joint FDA Advisory Committee Recommendations Regarding Pediatric Over-the-Counter Cough and Cold Medicines 2Health News:DuPont Responds to Spelter, W.Va., Lawsuit Decision 2Health News:Childlessness Bothers Men More Than Women 2Health News:Childlessness Bothers Men More Than Women 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: